Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkinxxxs Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial

Sureda, A; Pilar Gonzalez, A; Nunez, J; Briones, J; De la Cruz, F; Domenech Eva, D; Maria Hernandez, F; JoseTerol, M; Amutio, E; Cordoba, R; Martinez, C; Moreno, M; Izquierdo, AR; Del Campo, R; Greil, R; Romero, S; Garcia-Sanz, R BLOOD. 2021; 138:

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Bishop, MR; Dickinson, M; Purtill, D; Barba, P; Santoro, A; Hamad, N; Kato, K; Sureda, A; Greil, R; Thieblemont, C; Morschhauser, F; Janz, M; Flinn, IW; Rabitsch, W; Kwong, YL; Kersten, MJ; Minnema, MC; Holte, H; Chan, EHL; Martinez-Lopez, J; Mueller, AMS; Maziarz, RT; McGuirk, JP; Bachy, E; Le Gouill, S; Dreyling, M; Harigae, H; Bond, DA; Andreadis, C; McSweeney, PA; Kharfan-Dabaja, MA; Newsome, S; Degtyarev, E; Del Corral, C; Andreola, G; Masood, A; Schuster, SJ; Jaeger, U; Borchmann, P; Westin, JR BLOOD. 2021; 138:

Nivolumab (NIVO) plus chemotherapy (chemo) or NIVO plus ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first report of the CheckMate 648 study

Greil, R; Chau, I; Doki, Y; Ajani, JA; Xu, J; Wyrwicz, L; Motoyama, S; Ogata, T; Kawakami, H; Hsu, CH; Adenis, A; el Hajbi, F; Di Bartolomeo, M; Braghiroli, MI; Holtved, E; Xynos, I; Liu, X; Lei, M; Kondo, K; Kato, K; Kitagawa, Y ONCOL RES TREAT. 2021; 44: 81-82.

Phase Ib study of the anti-TGF-beta monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.

Bauer, TM; Lin, CC; Greil, R; Goebeler, ME; Huetter-Kroenke, ML; Garrido-Laguna, I; Santoro, A; Perotti, A; Spreafico, A; Yau, T; Joerger, M; Cremasco, V; Dostalek, M; Pelletier, M; Barys, L; Lu, D; Katsanou, V; Fabre, C; Doi, T J CLIN ONCOL. 2021; 39(15):

Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.

Awada, A; Ochsenreither, S; Eefsen, RL; Arnold, D; Yachnin, J; Pfeiffer, P; Jungels, C; Greil, R; Poulsen, L; Van Cutsem, E; Thorsson, L; Svedman, C; Garcia-Ribas, I; Collignon, J J CLIN ONCOL. 2021; 39(15):

Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with microsatellite stable (MSS) colorectal cancer (CRC)

Gadea, OSS; Greil, R; De Jonge, MJA; Tan, D; Jerusalem, G; Damian, S; Grell, P; Wainberg, Z; Wolf, J; Joerger, M; Carlino, MS; Kasper, S; Yap, TA; Otero, J; Yang, X; Nesbitt, V; Kim, J; Lee, LH; Choudhury, S; Leal, TA ANN ONCOL. 2021; 32: S552-S553.

Treatment landscape of HER2-positive metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry

Gampenrieder, SP; Rinnerthaler, G; Tinchon, C; Petzer, AL; Balic, M; Heibl, S; Zabernigg, A; Egle, D; Sandholzer, M; Roitner, F; Andel, J; Pichler, P; Hager, C; Hubalek, M; Knauer, M; Singer, CF; Greil, R ANN ONCOL. 2021; 32: S487-S488.

ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor (HER2) positive, early breast cancer (eBC) observing real-life extended adjuvant treatment with neratinib and concurrent use of the eHealth solution CANKADO

Harbeck, N; Luftner, D; Breitenstein, U; Jackisch, C; Muller, V; Schmidt, M; Balic, M; Rinnerthaler, G; Schwitter, M; Zaman, K; Wrobel, D; Guth, D; Terhaag, J; Zaiss, M; Schinkothe, T; Bartsch, R ANN ONCOL. 2021; 32: S444-S444.

Nadunolimab (CAN04), a first-in-class monoclonal antibody against IL1RAP, in combination with chemotherapy in subjects with pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC)

Awada, AH; Zematis, M; Ochsenreither, S; Eefsen, RL; Arnold, D; Cicenas, S; Yachnin, J; Pfeiffer, P; Paz-Ares, L; Jungels, C; Greil, R; Poulsen, LO; Van Cutsem, E; Ribas, IG; Thorsson, L; Collignon, JJ ANN ONCOL. 2021; 32: S602-S603.

Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial

Bianchini, G; Dugo, M; Huang, CS; Egle, D; Bermejo, B; Seitz, RS; Nielsen, TJJ; Zamagni, C; Thill, M; Anton, A; Russo, S; Ciruelos, EM; Schweitzer, BL; Greil, R; Semiglazov, V; Gyorffy, B; Valagussa, P; Viale, G; Callari, M; Gianni, L ANN ONCOL. 2021; 32: S1283-S1284.